Clinical trial NCT04906096: Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL
Official title: A Phase 2 Study of Paxalisib (GDC-0084) in Recurrent or Refractory Primary Central Nervous System Lymphoma (PCNSL)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Primary Central Nervous System Lymphoma
Non-Hodgkin Lymphoma of Extranodal Site
Keywords: Primary Central Nervous System Lymphoma
Non-Hodgkin Lymphoma of Extranodal Site
Lead sponsor: Dana-Farber Cancer Institute
Sponsor class: OTHER
Collaborators: name: Kazia Therapeutics Limited
First posted: 2021-05-28
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This research study is studying a drug called Paxalisib (GDC-0084) as a possible treatment for primary central nervous system lymphoma (PCNSL)

Detailed description: This is an open-label, phase 2 study to determine the efficacy of Paxalisib (GDC-0084) in 25 patients with recurrent or refractory primary central nervous system lymphoma (R/R PCNSL.

* The name of the study drug involved in this study is Paxalisib (GDC-0084).
* The research study procedures include: screening for eligibility and study treatment including evaluations and follow up visits.
* It is expected that about 25 participants will take part in this research study for up to 24 months as long as there is no serious side effects and disease progression.

This research study is a Phase 2 clinical trial. Phase 2 clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. The U.S. Food and Drug Administration (FDA) has not approved Paxalisib for this specific disease but it has been approved for other uses.

Eligibility criteria: Inclusion Criteria:

* Participants must be able to understand and willing to sign a written informed consent document.
* Participant must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol-related procedures that are not part of normal subject care.
* Participant must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and other requirements of the study.
* Participants must be at least 18 years old on day of signing informed consent.
* Participants must have a Karnofsky Performance Status (KPS) ≥ 70
* Participants must have histologically confirmed R/R primary DLBCL CNS lymphoma (from brain biopsy, CSF or vitreous biopsy).
* Participants should have evidence of refractory or recurrent disease on MRI with measurable or evaluable enhancing disease.
* Participants must have recovered to ≤ grade 1 or pre-treatment baseline from clinically significant toxic effects of prior therapy; exception, participants with ≤ grade 2 neuropathy may be eligible.
* Participant with dexamethasone requirement of ≤ 8mg/day or bioequivalent with corticosteroid usage at a stable or decreasing dose 2 weeks prior to screening.
* Participants must be able to undergo MRI.
* Participants must demonstrate adequate as defined below (all screening labs should be performed within 14 days of treatment initiation):

  * Hematology

    * White Blood Count (WBC) ≥ 2 K/µL
    * Platelet count ≥ 100 K/µL
    * Absolute Neutrophil Count ≥ 1.5 K/µL
    * Hemoglobin \> 9.0 g/dL or ≥ 5.6 mmol/L (Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks)
  * Biochemistry

    * Serum creatinine ≤1.5 x institutional ULN OR Measured or calculated creatinine clearance ≥30 mL/min for participant with creatinine levels \>1.5 × institutional ULN (Creatinine clearance should be calculated per institutional standard)
    * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN (≤5 × ULN for participants with liver metastases)
    * Total bilirubin (TBILI) ≤ 1.5 x institutional ULN (except subjects with Gilbert Syndrome who must have a total bilirubin level of \< 3.0 x institutional ULN) OR Direct bilirubin ≤ULN for participants with total bilirubin levels \>1.5 × ULN)
* Women of childbearing potential (WOCBP) must have a negative serum pregnancy within 72 hours prior to registration.
* WOCBP who are sexually active must use highly effective methods of contraception during treatment and for 28 days after the last dose of paxalisib. For male subjects with a pregnant or non-pregnant WOCBP partner, contraception measures are required during treatment and for 28 days after the last dose of paxalisib.

The subject, in consultation with the investigator, will select the most appropriate method of contraception from the permitted list of contraception methods, and site personnel will instruct the subject in its consistent and correct use as needed.

In addition, the investigator will instruct the subject to notify the site immediately if pregnancy of the subject or their partner is known or suspected.

Highly effective methods of contraception are those that, alone or in combination, result in a failure rate of less than 1% per year when used consistently and correctly and include:

* Established use of oral, injected, or implanted hormonal methods of contraception
* Correctly placed intrauterine device (IUD) or intrauterine system (IUS)
* Male condom or female condom used WITH a spermicide (i.e., foam, gel, film, cream)
* Male sterilization with appropriately confirmed absence of sperm in the post-vasectomy ejaculate
* Bilateral tubal ligation or bilateral salpingectomy

Exclusion Criteria:

* Participants unable to undergo MRI brain.
* Participants with active systemic disease.
* Participants with uncontrolled intercurrent illness.
* Participants with prior exposure to mTOR/PI3K inhibitors
* Prior malignancy (or any other malignancy requiring active treatment), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, superficial bladder cancer or other cancer from which the subject has been disease free for ≥ 3 years.
* Participants who have received prior systemic anti-cancer therapy including investigational agents or radiotherapy within 4 weeks OR 5 half-lives prior to dosing, whichever is shorter. Note: Participants must have recovered from all AEs due to previous therapies to ≤Grade 1 or baseline. Participants with ≤Grade 2 neuropathy may be eligible.
* Participants who have difficulty with or are unable to swallow oral medication or have significant gastrointestinal disease that would limit absorption of oral medication.
* Known history of infection with HIV, prior history of PML or any active significant infection (eg, bacterial, viral, or fungal).
* Known history of hypersensitivity or anaphylaxis to paxalisib including active product or excipient components.
* Requires treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor/inducer which may have an effect of the metabolism of paxalisib.
* Participants with uncontrolled medical comorbidities per investigator discretion including but not limited to interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, pre-exisiting Crohn's disease or ulcerative colitis or pre-existing chronic condition resulting in baseline grade 2 or higher diarrhea.
* Participants with type I diabetes mellitus, participants with uncontrolled type II diabetes mellitus,despite being on oral anti-diabetic medication. , participants with Type II diabetes mellitus that are well controlled on insulin . Uncontrolled diabetes is defined as HbA1c \>9% in addition to fasting glucose\>140mg/dL on at least 2 occasions within 14 days prior to registration
* Participants with uncontrolled hypertension despite optimal medical management (per investigator's assessment).
* Hepatitis B or C serologic status: subjects who are hepatitis B core antibody (anti-HBc) positive and who are hepatitis B surface antigen (HBsAg) negative will need to have a negative polymerase chain reaction (PCR) and must be willing to undergo DNA PCR testing during the study to be eligible. Those who are HBsAg positive or hepatitis B PCR positive will be excluded. Subjects who are hepatitis C antibody positive will need to have a negative PCR result to be eligible. Those who are hepatitis C PCR positive will be excluded.
* Breast feeding or pregnant
* Concurrent participation in another therapeutic trial.

Primary outcomes:
measure: Number of participants with Objective Response Rate (ORR)
timeFrame: Up to 24 Months
Secondary outcomes:
measure: Number of participants with Durable Objective Response Rate (ORR)
timeFrame: Up to 24 Months
measure: Overall Survival
timeFrame: Up to 24 Months
measure: Progression Free Survival (PFS)
timeFrame: up to 24 Months
measure: Number of cumulative treatment-emergent adverse events (TEAEs)
timeFrame: up to 24 Months
Other outcomes:
Locations:
city: Boston
country: United States
facility: Brigham and Women's Hospital
state: Massachusetts
city: Boston
country: United States
facility: Dana Farber Cancer Institute
state: Massachusetts
Study officials:
affiliation: Dana-Farber Cancer Institute
name: Lakshmi Nayak, MD
role: PRINCIPAL_INVESTIGATOR
References: